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. Introduction
he potential benefits of antiplatelet therapy for atheroscle-
otic cardiovascular (CV) disease have been amply demon-
trated over the past 2 decades, especially with regard to the
ole of thienopyridine drugs in preventing stent thrombosis.
owever, antiplatelet agents increase the risk of bleeding
ssociated with mucosal breaks in the upper and lower
astrointestinal (GI) tract. Rational use of thienopyridines is
ased on weighing their risks against their benefits. The
agnitude of the risks may vary among patients, based on
heir history and clinical characteristics, as may the magni-
ude of the benefits.
An earlier Expert Consensus Document, “Reducing the
I Risks of Antiplatelet and NSAID Use,” recommended
he use of a proton pump inhibitor (PPI) in patients with
isk factors for upper GI bleeding treated with dual anti-
latelet therapy (1). Since its publication, evidence of a
otential adverse drug interaction between PPIs and thien-
pyridines has emerged (2). Many recent investigations of
his potential adverse interaction have been performed,
sing a variety of research designs. It has been difficult for
ractitioners to assimilate this flood of information and to
evelop optimal treatment strategies for managing patients
ho might benefit from antiplatelet therapy, yet who mightuffer from GI bleeding. The purpose of this document is toeview critically the recent developments in this area, pro-
ide provisional guidance for clinical management, and
ighlight areas of future research necessary to address
urrent knowledge gaps.
.1. Summary of Findings and
onsensus Recommendations
1. Clopidogrel reduces major CV events compared with
placebo or aspirin.
2. Dual antiplatelet therapy with clopidogrel and aspirin,
compared with aspirin alone, reduces major CV events
in patients with established ischemic heart disease, and
it reduces coronary stent thrombosis but is not routinely
recommended for patients with prior ischemic stroke
because of the risk of bleeding.
3. Clopidogrel alone, aspirin alone, and their combination
are all associated with increased risk of GI bleeding.
4. Patients with prior GI bleeding are at highest risk for
recurrent bleeding on antiplatelet therapy. Other clin-
ical characteristics that increase the risk of GI bleeding
include advanced age; concurrent use of anticoagulants,
steroids, or nonsteroidal anti-inflammatory drugs
(NSAIDs) including aspirin; and Helicobacter pylori
infection. The risk of GI bleeding increases as the
number of risk factors increases.
5. Use of a PPI or histamine H2 receptor antagonist
(H2RA) reduces the risk of upper GI bleeding com-
pared with no therapy. PPIs reduce upper GI bleeding
to a greater degree than do H2RAs.
6. PPIs are recommended to reduce GI bleeding among
patients with a history of upper GI bleeding. PPIs are
appropriate in patients with multiple risk factors for GI
bleeding who require antiplatelet therapy.
7. Routine use of either a PPI or an H2RA is not
recommended for patients at lower risk of upper GI
bleeding, who have much less potential to benefit from
prophylactic therapy.
8. Clinical decisions regarding concomitant use of PPIs
and thienopyridines must balance overall risks and
benefits, considering both CV and GI complications.
9. Pharmacokinetic and pharmacodynamic studies, using
platelet assays as surrogate endpoints, suggest that
concomitant use of clopidogrel and a PPI reduces the
antiplatelet effects of clopidogrel. The strongest evi-
dence for an interaction is between omeprazole and
clopidogrel. It is not established that changes in these
surrogate endpoints translate into clinically meaningful
differences.
0. Observational studies and a single randomized clinical
trial (RCT) have shown inconsistent effects on CV
outcomes of concomitant use of thienopyridines and
PPIs. A clinically important interaction cannot be
excluded, particularly in certain subgroups, such as poor
metabolizers of clopidogrel.
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function testing in managing therapy with thienopyri-
dines and PPIs has not yet been established.
. Role of Thienopyridines in CV Disease
hienopyridine therapy has been evaluated as an alternative
o or in addition to aspirin treatment (“dual antiplatelet
herapy”) to reduce CV events. The absolute risk reduction
rom thienopyridines is greater in patients at higher CV
isk, particularly those with acute coronary syndromes
ACS) or patients who have had a coronary stent implanted.
In patients with ACS without ST-segment elevation,
ual antiplatelet therapy with clopidogrel plus aspirin re-
uced the risk of cardiac death, myocardial infarction (MI),
r stroke from 11.4% to 9.3%, compared with aspirin alone,
rrespective of whether patients were revascularized or
reated medically (3) but increased major bleeding from
.7% to 3.7%. In patients with ST-segment elevation MI
reated with fibrinolytics, the addition of clopidogrel to
spirin reduced major CV events over 30 days from 10.9%
o 9.1% but increased major bleeding from 1.7% to 1.9%
4,5).
Dual antiplatelet therapy with aspirin and clopidogrel
educes stent thrombosis following percutaneous coronary
ntervention (PCI) (6). Patients who are implanted with a
are-metal stent are recommended to receive at least 1
onth of clopidogrel, and patients receiving a drug-eluting
tent are recommended to receive dual therapy for at least 12
onths. In patients with atrial fibrillation who are unable to
ake vitamin-K antagonists, adding clopidogrel to aspirin
educed the rate of major vascular events (7.6% to 6.8%) and
troke (3.3% to 2.4%) compared with aspirin alone but with
greater risk of bleeding—2.0% per year (7).
In patients with established atherosclerotic CV disease,
lopidogrel alone reduced (5.8% to 5.3%) the combined risk
f major CV events, ischemic stroke, MI, and vascular death
ompared with aspirin alone (8) and led to less GI bleeding
2.7% to 2.0%). Clopidogrel is recommended as an alterna-
ive agent for patients with CV disease unable to take
spirin (9–12).
In the primary prevention setting, dual antiplatelet ther-
py with clopidogrel plus aspirin did not significantly reduce
ajor CV events compared with aspirin alone (6.8% versus
.3%) but increased severe bleeding (1.3% to 1.7%) (13).
atients with recent ischemic stroke or transient ischemic
ttack treated with clopidogrel plus aspirin had an insignif-
cant reduction in major CV events (16.7% to 15.7%)
ompared with aspirin alone and experienced more life-
hreatening hemorrhages (1.3% to 2.6%) (14).
Prasugrel is a new thienopyridine derivative with a rapid
nset and consistent inhibition of platelet aggregation. In
atients with ACS and planned PCI, prasugrel reduced
ajor CV events from 12.1% to 9.9% compared with nlopidogrel but increased major bleeding from 1.8% to 2.4%
nd fatal bleeding from 0.1% to 0.4% (15).
Ticagrelor, a novel, reversible, direct-acting P2Y12 recep-
or blocker (not yet approved for use in the United States)
educed the primary endpoint of vascular death, MI, or
troke from 11.7% to 9.8% compared with clopidogrel, with
o significant difference in major bleeding (11.6% versus
1.2%) but with an increased risk of noncoronary artery
ypass graft major bleeding (3.8% to 4.5%) (16).
For patients with ischemic stroke or transient ischemic
ttack, antiplatelet therapy with aspirin, clopidogrel, or the
ombination of dipyridamole and aspirin is recommended
o prevent recurrent stroke, but the combination of clopi-
ogrel and aspirin is not recommended (17), and prasugrel
s contraindicated (15).
. Risk of GI Bleeding and Related Mortality
ssociated With Clopidogrel Alone
r in Combination
I bleeding among patients receiving antiplatelet therapy
an develop from many different lesions and anatomic sites.
pper GI bleeding may be due to esophagitis (18) or peptic
lcer disease related to H. pylori infection, or aspirin or other
SAIDs (19). These mucosal breaks are aggravated by the
ntiplatelet effects of thienopyridines, promoting bleeding.
leeding from other GI sites is also exacerbated by anti-
latelet therapy (20–27).
Several risk factors for GI bleeding in the setting of
ntiplatelet therapy have been reported consistently. A
istory of bleeding or other complications of peptic ulcer
isease is the strongest risk factor for subsequent upper GI
leeding (28). Advanced age also significantly increases the
bsolute risk of upper GI bleeding. Use of anticoagulants,
teroids, or NSAIDs has also been shown to be consistent
redictors for GI bleeding, as has H. pylori infection
29–35). The relative risk (RR) of GI bleeding increases
ith the number of adverse risk factors present in an
ndividual patient (36).
The risk of GI bleeding associated with thienopyridines
as been assessed in several case-control studies (Online
able 1) and in RCTs with prospectively assessed GI
leeding safety endpoints (Online Table 2). In head-to-
ead randomized trials of aspirin and clopidogrel, the risk of
I bleeding was higher in patients treated with aspirin
Online Table 2), although the absolute risk difference was
mall.
Dual antiplatelet therapy with clopidogrel and aspirin
ncreased the risk of GI bleeding by 2- to 3-fold compared
ith aspirin alone in randomized trials (Online Table 2),
ut the absolute risk increase was in the range of 0.6% to
.0%. Two RCTs (3,7) provide specific data on GI bleeding
isk associated with dual antiplatelet therapy, demonstrating
n RR of 1.78 (95% confidence interval [CI]: 1.25 to 2.54;
umber needed to harm [NNH] of 130) and 1.96 (95% CI:
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f GI bleeding in routine practice among patients who are
ess selected and not as closely monitored as patients in
linical trials. In a cohort of Tennessee Medicaid patients
reated with clopidogrel, the rate of upper GI bleeding was
.2% per year (36).
There are few data on the mortality attributable to GI
leeding in patients on clopidogrel alone or on dual anti-
latelet therapy. In studies of varying duration and design,
he case fatality rates for GI bleeding associated with dual
ntiplatelet therapy have been low (0% to 0.3%) (3,29–31).
evertheless, the RR for death from a GI bleed has been
stimated at 2.5 (37), and GI bleeding appears to be a
ignificant predictor of death, even after adjustment for CV
orbidity, age, sex, diabetes, PCI status, and concomitant
herapy (37,38).
. Strategies to Prevent
hienopyridine-Related Upper GI Bleeding
hienopyridines do not cause ulcers or erosions of the
igestive tract (39), but their antiplatelet effects may pro-
ote bleeding at the site of preexisting lesions caused by the
se of aspirin or NSAIDs, or infection with H. pylori (40).
pper GI bleeding in the setting of thienopyridine use may
e reduced by suppressing gastric acid production, thereby
romoting healing of peptic ulcers and mucosal erosions, as
ell as by stabilizing thrombi (41). Acid production can be
uppressed either by H2RAs or by PPIs; the efficacy of each
as been examined to prevent GI bleeding related to
ntiplatelet use.
.1. Histamine H2 Receptor Antagonists
he use of H2RAs can suppress gastric acid production by
7% to 68% over 24 hours (42,43), and standard doses have
modest protective effect in patients taking aspirin. In a
andomized trial of 404 patients with peptic ulcers or
sophagitis who were taking aspirin, fewer gastroduodenal
lcers developed over 12 weeks among patients assigned to
amotidine (3.8%) than to placebo (23.5%; p0.0002) (18).
n another study, however, H2RAs did not significantly
rotect clopidogrel users (RR: 0.83; 95% CI: 0.20 to 3.51)
44). No randomized trials have directly compared PPIs
ith H2RAs in patients with CV disease on antiplatelet
herapy. However, observational data suggest PPIs may be
ore effective than H2RAs in preventing upper GI bleed-
ng. In a cohort of 987 patients who were prescribed aspirin
nd clopidogrel, PPI use led to a greater reduction in upper
I bleeding (odds ratio [OR]: 0.04; 95% CI: 0.002 to 0.21)
han H2RA use (OR: 0.43; 95% CI: 0.18 to 0.91) (30).
.2. Proton Pump Inhibitors
PIs reduce gastric acid secretion for up to 36 hours (45).
bservational data suggest that PPIs reduce the risk of GIleeding in patients on antiplatelet therapy. In 1 cohort ttudy, the baseline clopidogrel-related gastroduodenal
leeding risk of 1.2% per year was reduced by 50% in
atients prescribed a PPI (36). In this same study, PPI use
educed the absolute risk of GI bleeding by 2.8% per year
mong patients with 3 risk factors for GI bleeding. In a
arge case-control study comparing 2,779 patients with
ndoscopically confirmed upper GI hemorrhage with 5,532
ontrols, concomitant use of a PPI and a thienopyridine was
ssociated with less upper GI bleeding (RR: 0.19; 95% CI:
.07 to 0.49) than thienopyridine use alone (44). Smaller
ohort studies confirm similar risk reduction with concur-
ent PPI prescription (31). In the results of a recent
andomized trial (46), patients with CV disease taking
nteric-coated aspirin who were randomized to receive
lopidogrel plus omeprazole had fewer GI events (i.e., a
omposite outcome of overt or occult bleeding, symptomatic
astroduodenal ulcer or erosion) than patients randomized
o receive clopidogrel alone (hazard ratio [HR]: 0.34; 95%
I: 0.18 to 0.63).
. Drug Metabolism: Thienopyridine,
2RA, and PPI
.1. Thienopyridine Metabolism
lopidogrel is a pro-drug converted in vivo to an active
etabolite that irreversibly binds to the platelet adenosine
iphosphate (ADP) P2Y12 receptor, thereby inhibiting
latelet aggregation. The bioavailability of the active me-
abolite is determined by intestinal absorption, which may
e influenced by an ABCB1 polymorphism, and by metab-
lism through the cytochrome P-450 pathway (47). Clopi-
ogrel is activated in a 2-step process (Figure 1A) mediated
y oxidative biotransformation in the liver, in which
YP2C19 and CYP3A have particularly important roles
Figure 1A) (48,49). The parent compound clopidogrel, and
o a lesser extent 2-oxo-clopidogrel, are both substrates and
nhibitors of CYP1A2, CYP2B6, and CYP2C19 (50).
lopidogrel and 2-oxo-clopidogrel are extensively hydro-
yzed to inactive metabolites, potentially magnifying the
ffects of CYP2C19 inhibitors and polymorphisms (51).
owever, redundant pathways (Figure 1A) for activation of
lopidogrel may mitigate the effect of inhibitors and reduced
unction polymorphisms of CYP450 isoenzymes in vitro
49,52).
Prasugrel is also a pro-drug that requires biotransforma-
ion to active metabolites by cytochrome P-450 enzymes,
ncluding CYP3A isoforms, CYP2B6, CYP2C9, and
YP2C19 (Figure 1A). Prasugrel is hydrolyzed to a thiolac-
one derivative in the intestine and then oxidized to its active
etabolite in both the intestine and the liver (Figure 1A)
51,53). Reduced-function CYP2C19 alleles are not be-
ieved to have a clinically meaningful effect in prasugrel-
reated patients (54).
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Concomitant Use of PPI and Thienopyridines ECD December 7, 2010:2051–66Ticagrelor (AZD6140) is an orally active cyclopentyltria-
olopyrimidine adenosine triphosphate analog that revers-
bly inhibits P2Y12 platelet receptors (Figure 1B). Ticagre-
or, which is not yet approved in the United States, is an
ctive compound and is metabolized by CYP3A4 to an
ctive metabolite (55,56). Ticagrelor and its active metab-
lite are both metabolized and glucuronidated in the liver
efore elimination in the urine. Genetic variations in CYP
soenzymes do not appear to affect metabolism of ticagrelor.
Other frequently used CV medications are also metabo-
ized by the CYP450 system (51,52) and may interact with
hienopyridine metabolism. Of note are statins, which are
etabolized by the CYP450 system (51,52), and aspirin,
hich induces CYP2C19 (57).
.2. H2RA Metabolism
he H2RAs currently available in the United States (cime-
idine, ranitidine, famotidine, and nizatidine) vary in their
igure 1. Thienopyridine Metabolism
A) Clopidogrel and prasugrel; (B) ticagrelor. ATP indicates adenosine triphosphate; Cbility to inhibit gastric acid secretion. Hepatic metabolism Ps the dominant elimination pathway for orally administered
imetidine (60%), ranitidine (73%), and famotidine (50% to
0%) but not nizatidine (22%) (58). Cimetidine may inter-
ct with drugs metabolized via the cytochrome P-450
athway, as it inhibits CYP1A2, 2C9, 2C19, 2D6, 2E1, and
A4 (59–61). Although cimetidine might decrease the
iotransformation of clopidogrel by competitive inhibition
f CYP2C19, there have been no controlled studies of this
ypothesis. Ranitidine interacts weakly with cytochrome
-450 (58,62,63), and famotidine and nizatidine do not
ind to the cytochrome P-450 system and, therefore, have
ow potential to interact with clopidogrel (58,62).
.3. PPI Metabolism
ll PPIs used in the United States (omeprazole, esomepra-
ole, pantoprazole, rabeprazole, lansoprazole, and dexlanso-
razole) are weak bases converted to their active forms in
he acidic environment of active gastric parietal cells (64).
tochrome P-450; and hCE1 and 2, human carboxylesterases 1 and 2.PIs are metabolized by the hepatic cytochrome P-450
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December 7, 2010:2051–66 Concomitant Use of PPI and Thienopyridines ECDystem, predominantly CYP2C19, and, to a lesser extent,
YP3A4 (65). The studies assessing the degree to which
ifferent PPIs interact with CYP2C19 have yielded incon-
istent results, so no definitive conclusions can be drawn
omparing the pharmacokinetics and potential for drug
nteraction of the various PPIs with clopidogrel and
rasugrel.
. Hypotheses Regarding the
PI-Antiplatelet Interaction
.1. Reduced Biological Action of Clopidogrel
hrough Competitive Metabolic Effects of CYP2C19
oncomitant use of PPIs may competitively inhibit activa-
ion of clopidogrel by CYP2C19, thereby attenuating its
ntiplatelet effect. Coadministration of other CYP2C19-
nhibiting drugs may further reduce the efficacy of clopi-
ogrel and inhibition of platelet aggregation (66). The
eported interaction of clopidogrel and PPIs is consistent
ith a set of clinical pharmacokinetic findings referred to as
igh-risk pharmacokinetics (66). The risk of drug inefficacy
s greater when drug concentrations depend on variable
ctivity of a single metabolic pathway.
.2. Reduced Biological Action of Clopidogrel
elated to Genetic Polymorphisms
he potential for impaired antiplatelet activity is supported
y data on the effect of natural variations in CYP2C19
ctivity, based on genetic polymorphisms. The CYP2C19*2,
YP2C19*3, and CYP2C19*4 alleles decrease active metab-
lite production compared with the most common CYP2C19
enotype. Individuals who are heterozygous for loss-of-
unction alleles are “intermediate metabolizers,” and those who
re homozygous are “poor metabolizers.” CYP2C19 polymor-
hisms have been associated with reduced platelet inhibition
nd an increased rate of recurrent CV events (53,67,68).
educed platelet inhibition may be overcome with higher
lopidogrel doses (69), but any increased CV efficacy from
igher-dose treatment must be weighed against an increased
isk of GI bleeding (70).
The best characterized and most common loss-of-
unction polymorphism is the CYP2C19*2 allele (53),
hich is carried by 51% to 55% of Asians, 33% to 40% of
frican Americans, 24% to 30% of Caucasians, and 18% of
exican Americans (53,71–75). The antiplatelet effect of
lopidogrel varies directly with the number of loss-of-
unction alleles; 2 copies are associated with a 65% reduction
n clopidogrel antiplatelet efficacy and 1 copy with a 47%
eduction (71–75). The genetic variation in CYP2C19 is
ssociated with up to a 50% greater risk of adverse clinical
utcomes, including CV death, MI, or stroke, and a 3-fold
ncreased risk of stent thrombosis in patients receiving
lopidogrel (53,72). However, the CYP2C19*2 variant ap-
ears to account for only 12% of variation in platelet sggregability in response to ADP; and other factors, such as
iabetes, obesity, and acute ischemia (76), likely contribute
uch more to variability in platelet response (72,73,77).
. Evidence-Based Review:
PI and Clopidogrel/Thienopyridine
harmacokinetic and Pharmacodynamic Effect
latelet function tests serve as surrogate markers for the
linical effectiveness of antiplatelet drugs. The standard
latelet function test is aggregometry, which measures
DP-stimulated platelet aggregation in whole blood or
latelet-rich plasma. A more recent test quantifies phos-
horylation of vasodilator-stimulated phosphoprotein
VASP) in whole blood and appears to be a more specific
easure of clopidogrel-mediated inhibition of platelet ag-
regation. The newest test, the Verify Now P2Y12 assay, is
imilar to VASP. It has not been established that changes in
hese surrogate endpoints translate into clinically meaning-
ul differences.
Among 162 healthy subjects, carriers of at least 1
educed-function CYP2C19 allele had significantly less
nhibition of platelet aggregation on standard aggregometry
n response to clopidogrel than did noncarriers (53). The
ltrarapid metabolizer genotypes had the greatest platelet
nhibition from clopidogrel, and the poor metabolizer ge-
otypes had the least platelet inhibition.
The influence of omeprazole on the antiplatelet effects of
lopidogrel was assessed in a double-blind trial (78) of 124
atients after coronary stenting treated with aspirin and
lopidogrel. Patients randomized to omeprazole for 7 days
ad significantly less platelet inhibition, as measured by the
ASP method, than patients randomized to placebo. In
nother study of 104 patients given a higher maintenance
ose of 150 mg clopidogrel after coronary stenting (79),
atients randomized to omeprazole had significantly less
latelet inhibition on the VASP assay than patients ran-
omized to pantoprazole, with 44% clopidogrel nonre-
ponders in the omeprazole group compared with 23% in
he pantoprazole group (p0.04). In the PRINCIPLE–
IMI 44 (Prasugrel in Comparison to Clopidogrel for
nhibition of Platelet Activation and Aggregation–
hrombolysis In Myocardial Infarction 44) trial, patients
ndergoing PCI taking a PPI had significantly less platelet
nhibition with clopidogrel than those not on a PPI,
hereas patients taking prasugrel as well as a PPI had a
rend toward reduced-platelet inhibition (80).
In randomized trials that used ex vivo platelet assays as
urrogate clinical endpoints, patients treated with omepra-
ole demonstrated impaired clopidogrel response (78,79),
ven when a high antiplatelet dose was used. Studies of
ther PPIs have not demonstrated this effect (79,81), but
hese studies were conducted in different populations using
ifferent study designs. Few direct head-to-head compari-
on studies have been reported. The ongoing SPICE
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Concomitant Use of PPI and Thienopyridines ECD December 7, 2010:2051–66Evaluation of the Influence of Statins and Proton Pump
nhibitors on Clopidogrel Antiplatelet Effects) trial
NCT00930670) will directly compare the effects of com-
only prescribed PPIs (i.e., omeprazole, pantoprazole, es-
meprazole) and a H2RA (ranitidine) on ex vivo platelet
ggregation among 320 post-PCI patients who require dual
ntiplatelet therapy. Secondary outcomes include assess-
ent of clopidogrel resistance, prevalence of CYP2C19*2
olymorphism and its effect on PPI and antiplatelet activity,
ll-cause mortality, MI, revascularization, stroke, and GI
leeding at 1 year (82).
. PPI and Clopidogrel/Prasugrel
linical Efficacy
.1. Do PPIs Decrease Clinical Efficacy of
lopidogrel or Prasugrel?
bservational studies of different populations, sizes, and
egree of methodologic rigor have examined whether pa-
ients prescribed a PPI plus clopidogrel have an increased
isk of CV events compared with patients prescribed clopi-
ogrel alone (Online Table 3). The results are mixed: several
tudies have shown small but significant associations be-
ween PPI use and CV events, but others show no
ignificant association. The magnitude of the treatment
ffect in positive studies has been modest, with risk ratios
2.0. Whether differences in study results are because of
ifferences in confounding factors between study groups
annot be determined. In observational studies, PPIs may
e selectively prescribed to higher-risk patients, poten-
ially biasing the estimated CV risk (36). Small, yet
ignificant, differences in common, clinically important
vents would, however, represent an important public
ealth issue.
The effect of PPIs on clinical efficacy has been evaluated
etrospectively in nonrandomized cohorts within random-
zed trials. In a study of 13,608 patients randomized to
ither clopidogrel or prasugrel after PCI, use of PPI did not
ffect the outcome of a composite of CV death, MI, or
troke, either among clopidogrel-assigned patients (adjusted
R: 0.94; 95% CI: 0.80 to 1.11) or among the prasugrel-
ssigned patients (HR: 1.00; 95% CI: 0.84 to 1.20) (80). In
his study, there was no difference among the PPIs used,
ncluding omeprazole (n1,675), lansoprazole (n441),
someprazole (n613), and pantoprazole (n1,844). The
esults were similar among those with a reduced-function
YP2C19 allele. In the CREDO (Clopidogrel for Reduc-
ion of Events During Observation) trial, PPI use was
ssociated with an increased rate of CV events whether or
ot the patient was treated with clopidogrel (83). The
vidence from these studies and observational comparisons
s inconclusive regarding the clinical effects of concomitant
se of a PPI and a thienopyridine. l.2. Randomized Clinical Trials
nly 1 RCT has examined the potential interaction be-
ween clopidogrel and PPIs with CV events as the outcome.
n a double-blind, placebo-controlled trial (46), 3,761
atients with either ACS or PCI were randomized to a
xed-dose combination of clopidogrel and omeprazole
75/20 mg) or clopidogrel alone. All patients received
spirin. The data from this trial revealed no significant
ifference in a composite CV endpoint (MI, stroke, coro-
ary artery bypass graft, PCI, CV death) for patients on the
xed-dose combination compared with clopidogrel alone
HR: 0.99; 95% CI: 0.68 to 1.44), but fewer GI adverse
vents (HR: 0.34; 95% CI: 0.18 to 0.63). However, the
tudy was halted short of its planned enrollment and
uration; and the number of CV events was low (55 versus
4 CV events). Consequently, the confidence limits for CV
vents are broad and do not exclude a clinically important
ncrease in risk of up to 44%.
.3. Does the Choice of PPI Matter?
harmacokinetic studies in vitro have suggested that all
PIs inhibit CYP2C19 to varying degrees, but the relative
agnitude of inhibition varies by specific PPI and labora-
ory assay used. Pharmacodynamic studies using ADP-
timulated platelet aggregation in patients treated with
lopidogrel suggest a variable inhibitory effect of different
PIs (80,84,85), but few head-to-head comparison studies
ave been performed.
In the combined analysis of 2 trials of clopidogrel and
rasugrel, the rate of CV death, MI, or stroke was similar
or all PPIs and no different than the rate in patients not
aking a PPI (80). A nested case-control study of patients
eceiving clopidogrel after MI suggested pantoprazole may
ncrease the risk of rehospitalization for MI or PCI com-
ared with other PPIs (86). However, a retrospective cohort
tudy of 20,596 patients showed no effect of any PPI on the
requency of CV events among patients taking clopidogrel,
ith similar HRs for esomeprazole, lansoprazole, omepra-
ole, pantoprazole, and rabeprazole (36). Other observa-
ional studies of patients taking clopidogrel have suggested
hat the risk of CV events is similar for all PPIs (45,87,88).
Thus, although pharmacokinetic and pharmacodynamic
ata suggest varying inhibition by different PPIs of the
nzyme systems necessary to convert clopidogrel to its active
orm, there is no good evidence that these differences on
urrogate markers translate into meaningful differences in
linical outcomes. No prospective trials directly compare the
linical events of different PPIs in patients treated with
lopidogrel.
.3.1. Timing of Dosing to Minimize Interactions
ecause the plasma half-lives of both clopidogrel and all
vailable PPIs are less than 2 hours, interactions between
hese drugs might be minimized by separating the timing of
rug administration, even among poor CYP2C19 metabo-izers (45). In a crossover study examining 72 healthy
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December 7, 2010:2051–66 Concomitant Use of PPI and Thienopyridines ECDubjects who were administered standard-dose clopidogrel
300 mg followed by 75 mg daily) and a supratherapeutic
ose of omeprazole (80 mg daily), mean inhibition of
latelet aggregation was greater when the drugs were given
2 hours apart (89). Further studies will be required to
valuate this hypothesis, using appropriate drug doses and
eaningful clinical endpoints. Until data from such studies
re available, there is no solid evidence to recommend that
he dosing of PPIs be altered.
. Conclusions
.1. The Assessment of Epidemiologic Evidence
upporting a Significant Clinical Interaction
etween PPIs and Thienopyridines
hen assessing a possible causal link between an exposure
nd an outcome, it is recommended to consider: 1) the
trength of the association, 2) consistency of the association
cross different samples, 3) existence of a biologically plau-
ible mechanism of action, and 4) supportive experimental
vidence (90). In applying these principles to the concom-
tant use of PPIs and thienopyridines, we draw the follow-
ng conclusions:
. The magnitude of association in positive observational
studies reviewed is small to moderate (HR or OR: 2),
but associations of this magnitude in nonrandomized
observational studies may be due to residual differences
in patient characteristics between study groups. Large,
well-controlled randomized trials are necessary to
assess the validity of small-to-moderate magnitude
associations. The only available randomized trial
showed no significant association of omeprazole with
CV events, but the confidence limits on this null
finding include the possibility of up to a 44% relative
increase in CV risk.
. A significant association between PPI use and increased
CV events has been inconsistently demonstrated in
observational studies, with the majority of studies show-
ing no association. In addition, available studies mark-
edly vary in methodologic rigor.
. Although clinical studies with CV events as endpoints
are not definitive, the proposed mechanism is biologi-
cally plausible, given that a) clopidogrel users with
reduced-function genetic polymorphisms in CYP2C19
metabolism have increased rates of CV events; and b) in
vitro testing suggests that PPIs may inhibit CYP2C19
metabolism.
. Experimental pharmacodynamic data consistently indi-
cate that omeprazole diminishes the effect of clopidogrel
on platelets. Other pharmacodynamic studies have failed
to demonstrate a significant effect of other PPIs on
clopidogrel. In the absence of large-scale, randomized,
experimental studies that directly compare PPIs with
different pharmacokinetic properties, the evidence re-
mains weak for diminished antiplatelet activity associ- Pated with PPIs and thienopyridine coprescription. The
ongoing SPICE trial may provide additional answers and
address issues regarding the clinical relevance of such
interactions.
.2. Risk/Benefit Balance: GI Bleed Risk
ersus CV Event Risk
ll prescription drugs have favorable and unfavorable ef-
ects, and treatment decisions must be based on whether the
otential for benefit outweighs the potential for harm. The
V benefits of antiplatelet drugs are overwhelmingly doc-
mented for patients who have ACS and patients who
ndergo PCI. It is also well demonstrated that antiplate-
et drugs increase the risk of GI bleeding. The magnitude
f these benefits and risks in individual patients varies
epending on their characteristics (36). The challenge for
ealthcare providers is to determine the risk/benefit
alance for individual patients or subsets of the target
opulation.
PPIs are coprescribed with antiplatelet drugs for 1 rea-
on—to reduce the increased risk of GI complications
aused by antiplatelet drugs. The need for GI protection
ncreases with the number of risk factors for severe bleeding.
rior upper GI bleeding is the strongest and most consistent
isk factor for GI bleeding on antiplatelet therapy. Patients
ith ACS and prior upper GI bleeding are at substantial
V risk, so dual antiplatelet therapy with concomitant use
f a PPI may provide the optimal balance of risk and
enefit. Among stable patients undergoing coronary revas-
ularization, a history of GI bleeding should inform the
hoice of revascularization method; if a coronary stent is
elected to treat such patients, the risk/benefit tradeoff may
avor concomitant use of dual antiplatelet therapy and a
PI.
Advanced age; concomitant use of warfarin, steroids, or
SAIDs; or H. pylori infection all raise the risk of GI
leeding with antiplatelet therapy. The risk reduction with
PIs is substantial in patients with risk factors for GI
leeding and may outweigh any potential reduction in the
V efficacy of antiplatelet treatment because of a drug–drug
nteraction. Patients without these risk factors for GI
leeding receive little if any absolute risk reduction from a
PI, and the risk/benefit balance would seem to favor use of
ntiplatelet therapy without concomitant PPI. The reduc-
ion of GI symptoms by PPIs (i.e., treatment of dyspepsia)
ay also prevent patients from discontinuing their anti-
latelet treatment. The discontinuation of antiplatelet ther-
py in patients with GI bleeding may increase the risk of
V events (91).
.3. Are H2RAs a Reasonable Alternative
nd in Which Population?
2RAs are effective compared with placebo in decreasing
he risk of gastric and duodenal ulcers (92) caused by
SAIDs and antiplatelet therapy (18), but not as effective as
PIs (93,94). PPIs are also more effective than H2RAs for
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Concomitant Use of PPI and Thienopyridines ECD December 7, 2010:2051–66reventing ulcers in patients using high doses of NSAIDs
95) and are effective in decreasing GI bleeding in patients
rescribed aspirin or thienopyridines (36,96,97). Available
ata suggest PPIs are superior to H2RAs, but H2RAs may
e a reasonable alternative in patients at lower risk for GI
leeding, and in those who do not require PPI for refractory
astroesophageal reflux disease. Cimetidine can competi-
ively inhibit CYP2C19, so other H2RAs might be a better
hoice in patients treated with clopidogrel.
.4. Unanswered Questions and Areas for
uture Research
any gaps in knowledge exist regarding GI bleeding
mong patients prescribed thienopyridines. The pathophys-
ology of GI hemorrhage associated with thienopyridines is
ot fully understood and should be further elucidated.
etter data are needed on the incidence of GI bleeding
mong patients taking antiplatelet therapy, particularly in
elation to clinical factors that may alter the risk of bleeding.
he tradeoffs between bleeding risk and cardiovascular
enefits of antiplatelet therapy deserve further study. Clin-
cal trials of strategies to reduce the risk of GI bleeding
mong patients with CV disease on antiplatelet therapy,
articularly using the commonly prescribed PPIs and high- hose H2RAs, would provide direct evidence on the com-
arative effectiveness of alternative management strategies.
There is considerable variation among patients in re-
ponse to antiplatelet therapy, so the potential role of
aboratory testing in individualization of therapy should be
high priority for research. Either pharmacogenomic test-
ng for CYP2C19 variants or platelet function testing might
e used to tailor therapy by guiding the choice of drug
thienopyridines, PPIs, H2RAs), the choice of drug dose, or
oth. Although the concept of individually tailored therapy
s rational and attractive, empirical evidence for this ap-
roach is sparse. Clinical studies and randomized trials
omparing guided therapy with usual care are needed, as are
rials comparing different approaches to guided therapy
e.g., pharmacogenomic profiling versus platelet function
esting). Studies that compare different management op-
ions for patients with specific test results would also be
seful: For example, what are the effects on clinical out-
omes of using a higher dose of clopidogrel among patients
ho are either “poor metabolizers” on a genetic test or who
ave relatively little platelet inhibition on a functional assay?
inally, we need to evaluate the effect on clinical outcomes
f dosing schedules that minimize simultaneous exposure to
igh levels of a PPI and a thienopyridine.
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